Cargando…

Time to PSA rise differentiates the PSA bounce after HDR and LDR brachytherapy of prostate cancer

PURPOSE: To investigate the differences in prostate-specific antigen (PSA) bounce (PB) after high-dose-rate (HDR-BT) or low-dose-rate (LDR-BT) brachytherapy alone in prostate cancer patients. MATERIALS AND METHODS: Ninety-four patients with localized prostate cancer (T1-T2cN0), age ranged 50-81 year...

Descripción completa

Detalles Bibliográficos
Autores principales:	Burchardt, Wojciech, Skowronek, Janusz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2018
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5881590/ https://www.ncbi.nlm.nih.gov/pubmed/29619050 http://dx.doi.org/10.5114/jcb.2018.73786

Ejemplares similares

The use of nomograms in LDR-HDR prostate brachytherapy
por: Pujades, Ma Carmen, et al.
Publicado: (2011)

Tumour and immune cell dynamics explain the PSA bounce after prostate cancer brachytherapy
por: Yamamoto, Yoichiro, et al.
Publicado: (2016)

Low‐Dose‐Rate Prostate Brachytherapy (LDR‐PB) adopts postsurgical PSA value for definition of cure
por: Uribe, Jennifer, et al.
Publicado: (2020)

Minimal percentage of dose received by 90% of the urethra (%UD90) is the most significant predictor of PSA bounce in patients who underwent low-dose-rate brachytherapy (LDR-brachytherapy) for prostate cancer
por: Tanaka, Nobumichi, et al.
Publicado: (2012)

PSA bouncing after brachytherapy HDR and external beam radiation therapy: a study of 121 patients with minimum 5-years follow-up
por: Makarewicz, Roman, et al.
Publicado: (2009)

Is there any place for LDR brachytherapy for head and neck carcinomas in HDR era?
por: Fijuth, Jacek
Publicado: (2009)

Characteristics of PSA Bounce after Radiotherapy for Prostate Cancer: A Meta-Analysis
por: Darwis, Narisa Dewi Maulany, et al.
Publicado: (2020)

Vital role of volume and number of needles in HDR brachytherapy (HDR-BT) of prostate cancer
por: Chicheł, Adam, et al.
Publicado: (2009)

Permanent (125)I-seed prostate brachytherapy: early prostate specific antigen value as a predictor of PSA bounce occurrence
por: Mazeron, Renaud, et al.
Publicado: (2012)

HDR and LDR Brachytherapy in the Treatment of Lip Cancer: the Experience of the Catalan Institute of Oncology
por: Ayerra, Arrate Querejeta, et al.
Publicado: (2010)

HDR brachytherapy of prostate cancer – two years experience in Greater Poland Cancer Centre
por: Kanikowski, Marek, et al.
Publicado: (2009)

A Brief Review of Low-Dose Rate (LDR) and High-Dose Rate (HDR) Brachytherapy Boost for High-Risk Prostate
por: Fischer-Valuck, Benjamin W., et al.
Publicado: (2019)

HDR brachytherapy (HDR–BT) combined with stent placement in palliative treatment of esophageal cancer
por: Kanikowski, Marek, et al.
Publicado: (2009)

Comparative dosimetrical analysis of intensity-modulated arc therapy, CyberKnife therapy and image-guided interstitial HDR and LDR brachytherapy of low risk prostate cancer
por: Fröhlich, Georgina, et al.
Publicado: (2021)

Urinary PSA and Serum PSA for Aggressive Prostate Cancer Detection
por: Höti, Naseruddin, et al.
Publicado: (2023)

Modeled Early Longitudinal PSA Kinetics Prognostic Value in Rising PSA Prostate Cancer Patients after Local Therapy Treated with ADT +/− Docetaxel
por: Carrot, Aurore, et al.
Publicado: (2022)

Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer
por: Tomioka, Atsushi, et al.
Publicado: (2014)

Exponential Rise in Prostate-Specific Antigen (PSA) during Anti-Androgen Withdrawal Predicts PSA Flare after Docetaxel Chemotherapy in Patients with Castration-Resistant Prostate Cancer
por: Han, Kyung Seok, et al.
Publicado: (2015)

Prostate cancer-specific death in brachytherapy treated high-risk patients stratified by pre-treatment PSA
por: Merrick, Gregory S., et al.
Publicado: (2017)

Does normalizing PSA after successful treatment of chronic prostatitis with high PSA value exclude prostatic biopsy?
por: Azab, Sherif, et al.
Publicado: (2012)

Analysis of monotherapy prostate brachytherapy in patients with prostate cancer. Initial PSA and Gleason are important for recurrence?
por: Galego, Pedro, et al.
Publicado: (2015)

Association of Polymorphisms in the Prostate-Specific Antigen (PSA) Gene Promoter with Serum PSA Level and PSA Changes after Dutasteride Treatment in Korean Men with Benign Prostatic Hypertrophy
por: Park, Sung Woon, et al.
Publicado: (2010)

The Relationship between Prostate Biopsy Results and PSA and Free PSA Ratio Changes in Elevated Serum PSA Patients with and without Antibiotherapy
por: Duran, Mesut Berkan, et al.
Publicado: (2020)

Actual Contribution of Free to Total PSA Ratio in Prostate Diseases Differentiation
por: Prcic, Alden, et al.
Publicado: (2016)

Temperature Control of psaA Expression by PsaE and PsaF in Yersinia pestis
por: Quinn, Joshua D., et al.
Publicado: (2019)

Detection of prostate cancer with complexed PSA and complexed/total PSA ratio - is there any advantage?
por: Strittmatter, F, et al.
Publicado: (2011)

Zonal adjusted PSA density improves prostate cancer detection rates compared with PSA in Taiwanese males with PSA < 20 ng/ml
por: Chang, Tsung-Hsin, et al.
Publicado: (2020)

A Comparative Performance Analysis of Total PSA, Percentage Free PSA, PSA Velocity, and PSA Density versus the Detection of Primary Circulating Prostate Cells in Predicting Initial Prostate Biopsy Findings in Chilean Men
por: Murray, Nigel P., et al.
Publicado: (2014)

Prostate brachytherapy: HDR or seed implant
por: Das, K. R.
Publicado: (2006)

Usefulness of Total PSA Value in Prostate Diseases Diagnosis
por: Prcic, Alden, et al.
Publicado: (2016)

Clinical features of prostate-specific antigen bounce after (125)I brachytherapy for prostate cancer
por: Kubo, Katsumaro, et al.
Publicado: (2018)

Evaluation of the effect of prostate volume change on tumor control probability in LDR brachytherapy
por: Knaup, Courtney, et al.
Publicado: (2011)

Establishment of reference intervals for serum [−2]proPSA (p2PSA), %p2PSA and prostate health index in healthy men
por: Wu, Zhi-Yu, et al.
Publicado: (2019)

The effect of the frequency and duration of prostate specific antigen (PSA) measurement on PSA doubling time calculations in men with biochemically recurrent prostate cancer
por: Paller, CJ, et al.
Publicado: (2013)

Hyperfractionation of HDR brachytherapy – influence on doses and biologically equivalent doses in clinical target volume and healthy tissues
por: Skowronek, Janusz, et al.
Publicado: (2009)

Antigenic determinants of prostate-specific antigen (PSA) and development of assays specific for different forms of PSA.
por: Nilsson, O., et al.
Publicado: (1997)

Prognostic significance of a novel indicator (PSA(postd3)/PSA(pre)) for PSA recurrence in patients after radical prostatectomy
por: Zhou, Zhien, et al.
Publicado: (2019)

Clinical Use of [-2]proPSA (p2PSA) and Its Derivatives (%p2PSA and Prostate Health Index) for the Detection of Prostate Cancer: A Review of the Literature
por: Abrate, Alberto, et al.
Publicado: (2014)

Investigation of the relationship between endothelial nitric oxide synthase T786C polymorphism and PSA, PSA derivatives, and prostate cancer in the Turkish population
por: Balci, Senay, et al.
Publicado: (2023)

Exploration of the Value of Combined UA, IL-6, and fPSA/tPSA in the Diagnosis of Prostate Cancer
por: Tang, Qionghua, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hkhduhp9v7uiqg67lfc643e1st